Teva Pharmaceutical Industries (TEVA) Earnings Date & Reports
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer... Show more
TEVA is expected to report earnings to rise 12.64% to 59 cents per share on August 05
Teva Pharmaceutical Industries (TEVA) Q1 2026 Earnings Recap: Innovative Portfolio Drives Beat Despite Generics Headwinds
Key Takeaways
- Reported Q1 2026 revenues of $3,982 million, up 2% year-over-year (YoY) in U.S. dollars and beating consensus estimates of approximately $3.79 billion.
- Non-GAAP diluted earnings per share (EPS) of $0.53, in line with or slightly above expectations of $0.52 and flat YoY.
- GAAP diluted EPS improved to $0.31 from $0.18 in Q1 2025.
- Key innovative products shone: AUSTEDO sales up 41% YoY in local currency (LC), AJOVY up 35%, UZEDY up 62%.
- Generics revenues fell 16% YoY in LC, pressured by U.S. lenalidomide competition.
- 2026 non-GAAP EPS guidance lowered to $1.91-$2.11 due to Emalex acquisition; full-year revenue outlook held at $16.4-$16.8 billion.
Earnings Context and Why It Matters
Teva Pharmaceutical Industries' Q1 2026 earnings highlight its ongoing "Pivot to Growth" strategy amid challenges in generics and opportunities in innovative medicines. As a global leader in generics and branded drugs, Teva faces intense competition in mature products like lenalidomide generics while betting on high-growth therapies such as AUSTEDO for Huntington's disease. This report matters for investors tracking Teva's margin expansion—non-GAAP gross margin held steady at 52.9%—debt reduction efforts (net debt at $16.6 billion), and pipeline progress in biosimilars and neurology. With shares up significantly post-release, it underscores shifting investor focus to innovative revenue streams in a $1.5 trillion pharmaceutical industry.
Teva reported Q1 2026 revenues of $3,982 million, a 2% increase YoY in U.S. dollars (3% decline in LC), exceeding analyst consensus. Growth was propelled by the innovative portfolio, which surged 41% YoY in LC to $838 million, led by AUSTEDO ($578 million), AJOVY ($196 million), and UZEDY ($63 million). Offsetting this, generics revenues dropped 16% in LC, primarily from U.S. competition on Revlimid generics (lenalidomide).
Non-GAAP diluted EPS came in at $0.53, matching prior-year levels and meeting expectations, while GAAP EPS rose to $0.31. Non-GAAP operating income was $956 million (24.0% margin), adjusted EBITDA reached $1,055 million (up 1% YoY), and free cash flow improved to $188 million. U.S. revenues were flat at $1,534 million, Europe up 12% to $1,340 million, and international markets down 10%.
Guidance for 2026 was updated post-announcement of the Emalex Biosciences acquisition (ecopipam for Tourette's), incorporating a $700 million in-process research and development (IPR&D) charge. Revenue remains $16.4-$16.8 billion (in line with Street), but non-GAAP EPS narrowed to $1.91-$2.11 from prior $2.57-$2.77.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research workflow.
Market Reaction and Investor Sentiment
TEVA shares surged approximately 7% in premarket trading on April 29, 2026, reflecting positive reception to the earnings beat despite lowered full-year EPS guidance tied to the Emalex deal. Investors appeared encouraged by robust innovative product growth and maintained revenue outlook, offsetting generics weakness and acquisition-related charges. Sentiment focuses on Teva's strategic shift toward higher-margin specialties.
Forward Outlook and Key Factors to Monitor
Investors should watch the Q3 2026 close of the Emalex Biosciences acquisition, which adds ecopipam—a potential best-in-class therapy for Tourette syndrome—to Teva's pipeline. This deal, while dilutive short-term due to IPR&D costs, bolsters neurology focus alongside AUSTEDO and AJOVY expansions.
Biosimilars progress remains critical: PONLIMSI (denosumab) is FDA-approved, with U.S. launch underway; Xolair (omalizumab) biosimilar filing accepted. Upcoming catalysts include olanzapine long-acting injectable (LAI) NDA approval (potential Q4 2026 launch) and duvakitug Phase 2b data in ulcerative colitis and Crohn's disease.
Cost transformation targets $700 million in net savings by 2027, aiming for 30% non-GAAP operating margin. Free cash flow guidance of $2.0-$2.4 billion supports debt reduction and potential share repurchases. Monitor U.S. generics erosion, Europe growth, and overall innovative portfolio momentum amid patent cliffs and competition.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Advertisement
General Information
a manufacturer of generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients
Industry PharmaceuticalsGeneric